Page last updated: 2024-12-05

usnic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5646
CHEMBL ID1375951
CHEBI ID2264
SCHEMBL ID177774
MeSH IDM0198345
PubMed CID24211
CHEMBL ID242022
CHEMBL ID1314537
CHEBI ID38319
SCHEMBL ID1767536
MeSH IDM0198345

Synonyms (115)

Synonym
usinic acid
l-usnic acid
dibenzofuran-1,9bh)-dione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-
1,9bh)-dibenzofurandione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-
usnic acid ,
nsc5890 ,
wln: t b656 cv ev ho fu bht & jb1 dv1 kq l1 mq
usnic acid, (l)
nsc5889 ,
nsc8517
usno
125-46-2
usnic acid, (d)
KBIO1_001009
DIVK1C_001009
NCI60_004436
NCI60_004437
SDCCGMLS-0066516.P001
ai3-50457
usninsaeure [german]
(+-)-uanic acid
nsc 8517
2,6-diacetyl-1,2,3,9b-tetrahydro-7,9-dihydroxy-8,9b-dimethyldibenzofuran-1,3-dione
hsdb 7170
2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-1,3(2h,9bh)-dibenzofurandione
ccris 5518
einecs 204-740-7
brn 1299865
1,3(2h,9bh)-dibenzofurandione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-
SPECTRUM4_001811
SPECTRUM_000177
IDI1_001009
(+/-)-1,3(2h,9bh)-dibenzofurandione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-
2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-dibenzofuran-1,3-dione
2,6-diacetyl-1,2,3,9b-tetrahydro-7,9-dihydroxy-8,9b-dimethyldiben- zofuran-1,3-dione/ usno
SPECTRUM5_000541
BSPBIO_002869
NCGC00094823-01
KBIOGR_002446
KBIO3_002369
KBIOSS_000657
KBIO2_005793
KBIO2_003225
KBIO2_000657
SPECTRUM2_000744
SPBIO_000728
SPECTRUM3_001195
NINDS_001009
2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzo[b,d]furan-1,3(2h,9bh)-dione
NCGC00094823-02
HMS503I19
U0023
2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzofuran-1,3-dione
STK801335
2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-dibenzofuran-1,3-dione;usnic acid
A805384
AKOS005613032
NCGC00094823-03
chebi:2264 ,
CHEMBL1375951
BBL009902
CCG-40251
unii-0w584pfj77
FT-0627625
FT-0605175
S4953
SCHEMBL177774
7-hydroxy-(s)-usnate
Q-100111
usnic acid, antibiotic for culture media use only
CUCUKLJLRRAKFN-UHFFFAOYSA-N
(.+/-.)-usnic acid
2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzo[b,d]furan-1,3(2h,9bh)-dione #
DTXSID0040123
2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-9bh-dibenzofuran-1,3-dione, aldrichcpr
4,10-diacetyl-11,13-dihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.0^{2,7}]trideca-1(9),6,10,12-tetraene-3,5-dione
usnic-acid
HY-N0656
Q27105599
AS-18744
BRD-A85739295-001-03-6
CS-0009679
uanic acid
EN300-7388062
4,10-diacetyl-11,13-dihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.0,2,7]trideca-1(13),6,9,11-tetraene-3,5-dione
d-usnic acid
CHEBI:38319 ,
2,6-diacetyl-3,7,9-trihydroxy-8,9b-dimethyldibenzo[b,d]furan-1(9bh)-one
(+)-usnic acid
7562-61-0
NCGC00160165-01
AKOS000281081
CHEMBL242022 ,
2,6-diacetyl-3,7,9-trihydroxy-8,9b-dimethyldibenzofuran-1-one
CHEMBL1314537
FT-0636008
(+)-usnic acid from usnea dasypoga
usnic acid [inci]
usnic acid [mi]
21987-06-4
usnic acid [hsdb]
usnic acid [who-dd]
SCHEMBL1767536
2,6-diacetyl-3,7,9-trihydroxy-8,9b-dimethyl-9bh-dibenzofuran-1-one (usnic acid)
WEYVVCKOOFYHRW-UHFFFAOYSA-N
4,10-diacetyl-3,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.0(2,7)]trideca-1(13),3,6,9,11-pentaen-5-one
ICTZCAHDGHPRQR-UHFFFAOYSA-N
us9273021, usnic acid
bdbm209638
AKOS030500799
usninsaure
mfcd00065294
Q425335
AKOS040765315
usniacin-(+)

Research Excerpts

Overview

Usnic acid is an antibiotic metabolite produced by a wide variety of lichenized fungal lineages. It has been shown to exhibit antiproliferative properties. Its application is limited by poor drug-like properties and low specificity.

ExcerptReferenceRelevance
"Usnic acid is an antibiotic metabolite produced by a wide variety of lichenized fungal lineages. "( Novel methods to characterise spatial distribution and enantiomeric composition of usnic acids in four Icelandic lichens.
Abdelrahman, A; Andresson, OS; Christensen, EA; de Boer, HJ; Gylfason, AE; Heidmarsson, S; Jameson, CJ; Magnusson, KP; Murad, S; Oddsson, S; Olafsdottir, ES; Omarsdottir, S; Oppong-Danquah, E; Pedersen, SV; Snorradottir, BS; Szomek, M; Tasdemir, D; Thorsteinsdottir, M; Wang, X; Xu, M, 2022
)
2.39
"(+)-Usnic acid is a secondary metabolite of lichens belonging to the Usnea genus. "( Toxicity studies of (+)-usnic acid administered in feed to F344/N Nctr rats and B6C3F1/Nctr mice.
, 2022
)
1.59
"Usnic acid is an abundant characteristic secondary metabolite of lichens and the earliest lichen compound used commercially."( Advances in Research on Bioactivity, Toxicity, Metabolism, and Pharmacokinetics of Usnic Acid In Vitro and In Vivo.
Huang, C; Wang, C; Wang, H; Xuan, M, 2022
)
1.67
"Usnic acid is a secondary metabolite isolated predominately from lichen species and has been shown to exhibit antiproliferative properties, however its application is limited by poor drug-like properties and low specificity."( Divergent reactivity of usnic acid and evaluation of its derivatives for antiproliferative activity against cancer cells.
Gardiner, MG; Gimła, M; Gunawan, GA; Herman-Antosiewicz, A; Reekie, TA, 2023
)
1.94
"Usnic acid (UA) is a dibenzofuran derivative isolated from lichens."( Effects of the Dibenzofuran, Usnic Acid, on Inhibition of Ocular Biofilm Formation Due to Coagulase-Negative Staphylococci.
Akova, B; Kıvanç, M; Kıvanç, SA, 2023
)
1.92
"Usnic acid (UA) is a compound with multiple biological activities that make it useful in various industries, e.g., pharmaceutical, cosmetic, dentistry, and agricultural sectors. "( Methodological Aspects of Green Extraction of Usnic Acid Using Natural Deep Eutectic Solvents.
Dresler, S; Hanaka, A; Kulinowska, M; Skalska-Kamińska, A; Strzemski, M, 2023
)
2.61
"Usnic acid is a secondary metabolite extracted from lichen species and has many biological activities."( Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer.
Cansaran-Duman, D; Tanman, Ü; Yangın, S, 2020
)
1.5
"(+)-Usnic acid (UA) is a natural substance that displays pharmacological activity, but it is barely soluble in water, so it was included in liposomes in order to study its properties. "( Correlation of Physicochemical and Antimicrobial Properties of Liposomes Loaded with (+)-Usnic Acid.
Battista, S; Bellio, P; Celenza, G; Franceschini, I; Galantini, L; Giansanti, L; Mancini, G, 2020
)
1.34
"Usnic acid (UA) is a well-known hepatotoxin derived from lichens."( Review: Usnic acid-induced hepatotoxicity and cell death.
Kwong, SP; Wang, C, 2020
)
1.71
"Usnic acid is a dibenzofuran compound originating from Usnea diffracta Vain and has anti-inflammatory, antifungal, and anticancer activities."( Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity.
Jin, CH; Jin, HL; Jin, X; Li, MY; Ma, J; Piao, LX; Ri, M; Sun, TX; Wang, JY; Xing, Y; Xu, GH; Zhang, ZH; Zuo, HX, 2021
)
2.79
"Usnic acid (UA) is a secondary metabolite of lichens that exhibits a wide range of biological activities. "( New Hybrid Compounds Combining Fragments of Usnic Acid and Monoterpenoids for Effective Tyrosyl-DNA Phosphodiesterase 1 Inhibition.
Dyrkheeva, NS; Filimonov, AS; Ilina, ES; Lavrik, OI; Luzina, OA; Malakhova, AA; Medvedev, SP; Reynisson, J; Salakhutdinov, NF; Volcho, KP; Zakharenko, AL; Zakian, SM, 2021
)
2.33
"Usnic acid (UA) is a lichen-derived secondary metabolite with a unique dibenzofuran skeleton and is commonly found in lichenized fungi of the genera Usnea and Cladonia. "( Usnic acid and its derivatives for pharmaceutical use: a patent review (2000-2017).
Luzina, OA; Salakhutdinov, NF, 2018
)
3.37
"Usnic acid is a lichen compound which is extensively studied due to its cytotoxic, antiproliferative, antimicrobial, antiviral, antiprotozoal, and anti-inflammatory activities. "( Usnic acid reactive metabolites formation in human, rat, and mice microsomes. Implication for hepatotoxicity.
Galanty, A; Koczurkiewicz, P; Pękala, E; Piska, K; Podolak, I; Potaczek, J; Żmudzki, P, 2018
)
3.37
"Usnic acid is a unique polyketide produced by lichens. "( Identification of a putative polyketide synthase gene involved in usnic acid biosynthesis in the lichen Nephromopsis pallescens.
Geng, C; Hua, M; Li, C; Tian, F; Wang, Y; Yuan, X, 2018
)
2.16
"Usnic acid (UA) is a multifunctional bioactive lichen secondary metabolite with potential anti-cancer properties. "( The role of usnic acid-induced apoptosis and autophagy in hepatocellular carcinoma.
Cecener, G; Egeli, U; Eryilmaz, IE; Eskiler, GG; Tunca, B; Yurdacan, B, 2019
)
2.34
"Usnic acid (UA) is a secondary lichen metabolite extensively studied for the broad variety of biological features. "( Usnic Acid: Potential Role in Management of Wound Infections.
Donelli, G; Francolini, I; Piozzi, A, 2019
)
3.4
"Usnic acid (UA) is a lichenic secondary metabolite useful for the treatment of burn wounds thanks to its antimicrobial activity, particularly toward strains responsible for their infections. "( Bioadhesive polymeric films based on usnic acid for burn wound treatment: Antibacterial and cytotoxicity studies.
Calarco, P; Ceccarini, MR; Conte, C; Pagano, C; Perioli, L; Primavilla, S; Ricci, M; Scuota, S, 2019
)
2.23
"(+)-Usnic acid is a natural compound that exerts a potent antibacterial activity, however its clinical application is hampered by its scarce solubility in water."( Glucosylated liposomes as drug delivery systems of usnic acid to address bacterial infections.
Altieri, B; Francolini, I; Giansanti, L; Mancini, G; Mauceri, A; Piozzi, A, 2019
)
1.25
"Usnic acid is a naturally occurring dibenzofuran derivative found in several lichen species. "( Harmful effects of usnic acid on hepatic metabolism.
Bracht, A; Comar, JF; Moreira, CT; Oliveira, AL; Peralta, RM, 2013
)
2.16
"Usnic acid (UA) is a secondary metabolite abundantly found in lichens. "( Usnic acid inhibits growth and induces cell cycle arrest and apoptosis in human lung carcinoma A549 cells.
Kale, RK; Nambiar, D; Singh, N; Singh, RP, 2013
)
3.28
"Usnic acid is a secondary metabolite found in several species of lichens, organisms resulting from the symbiosis between fungi and algae. "( Anionic form of usnic acid promotes lamellar to nonlamellar transition in DPPC and DOPC membranes.
da Silva, JB; Lins, RD; Nadvorny, D, 2014
)
2.19
"Usnic acid is a dibenzofuran derivative found in several lichen species, which has been shown to possess several activities, including antiviral, antibiotic, antitumoral, antipyretic, analgesic, antioxidative and anti-inflammatory activities. "( Usnic acid protects LPS-induced acute lung injury in mice through attenuating inflammatory responses and oxidative stress.
Chen, XY; Chen, ZW; Feng, XX; Lai, XP; Liang, YZ; Liao, JB; Liu, YH; Mo, ZZ; Su, ZQ; Su, ZR; Zhang, X, 2014
)
3.29
"(+)-Usnic acid (1) is a common bioactive lichen-derived secondary metabolite with a characteristic dibenzofuran scaffold. "( Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies.
Akl, MR; Ebrahim, HY; El Sayed, KA; Elsayed, HE; Hill, RA, 2017
)
2.46
"Usnic acid is a prominent secondary lichen metabolite that has been used for various purposes worldwide. "( Review of usnic acid and Usnea barbata toxicity.
Ali, AA; Fang, JL; Frankos, VH; Guo, L; Leakey, JE; Lewis, SM; Mei, N; Shi, Q,
)
1.98
"Usnic acid is a lichen metabolite used as a weight-loss dietary supplement due to its uncoupling action on mitochondria. "( Effect of (+)-usnic acid on mitochondrial functions as measured by mitochondria-specific oligonucleotide microarray in liver of B6C3F1 mice.
Ali, AA; Allaben, WT; Branham, WS; Desai, VG; Fuscoe, JC; Joseph, A; Leakey, JE; Lee, T; Lewis, SM; Moland, CL, 2009
)
2.16
"(+)-usnic acid is a natural compound of low toxicity in mice, and low to medium dose of (+)-usnic acid dose not produce obvious cytotoxicity."( [Oral acute toxicity of (+)-usnic acid in mice and its cytotoxicity in rat cardiac fibroblasts].
Cheng, YB; Gu, N; Li, C; Li, XQ; Shi, L; Si, KW; Wei, LL; Yuan, YK, 2009
)
1.21
"Usnic acid (UA) is a secondary metabolite produced by lichens, which exhibits an anti-tumour activity."( In vitro and in vivo properties of usnic acid encapsulated into PLGA-microspheres.
Alves, AJ; Gonçalves, EC; Honda, NK; Nascimento, SC; Ribeiro-Costa, RM; Santos, NP; Santos-Magalhães, NS; Silva, NH, 2004
)
1.32
"Usnic acid is a component of nutritional supplements promoted for weight loss that have been associated with liver-related adverse events including mild hepatic toxicity, chemical hepatitis, and liver failure requiring transplant. "( Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.
Davis, JA; Dickmann, LJ; Foti, RS; Greene, RJ; Hill, JJ; Howard, ML; Pearson, JT; Rock, DA; Slatter, JG; Tay, JC; Wahlstrom, JL, 2008
)
2.03
"Usnic acid is a biosynthesis product characteristic of several epiphytic lichens such as Evernia, Cladonia and Parmelia. "( Antimitotic effects of usnic acid on different biological systems.
Alesiani, O; Campanella, L; Cardarelli, M; De Cicco Nardone, F; Ercole, P; Rossiello, F; Serino, G, 1997
)
2.05
"Usnic acid is an antibiotic substance from lichens."( Reversed-polarity capillary zone electrophoretic analysis of usnic acid.
Kreft, S; Strukelj, B, 2001
)
1.27
"Usnic acid is a normal component of lichen cells. "( Molecular characterization and action of usnic acid: a drug that inhibits proliferation of mouse polyomavirus in vitro and whose main target is RNA transcription.
Campanella, L; Delfini, M; Ercole, P; Iacoangeli, A; Risuleo, G, 2002
)
2.02

Effects

Usnic acid has a reported antibiotic activity and the lichen is utilized for medicinal purposes by Andean farmers.

Usnic acid has a reported antibiotic activity and the lichen is utilized for medicinal purposes by Andean farmers. Usnic acid is an ingredient of dietary supplements that cause liver failure.

ExcerptReferenceRelevance
"(+)-Usnic acid has a remarkable effect on T. "( [In vitro effect of (+)-usnic acid on Toxoplasma gondii tachyzoites].
Cheng, YB; Gu, N; Li, C; Li, XQ; Si, KW; Wei, LL; Yuan, YK, 2008
)
1.21
"Usnic acid has a strong and dose-dependent activity against H."( In vitro anti-Helicobacter pylori activity of usnic acid.
Aktepe, OC; Altindis, M; Asik, G; Cetinkaya, Z; Ciftci, IH; Kiyildi, N; Ozdemir, M; Safak, B, 2009
)
1.33
"Usnic acid has a reported antibiotic activity and the lichen is utilized for medicinal purposes by Andean farmers."( Occurrence of usnic acid in Usnea laevis Nylander (lichenized ascomycetes) from the Venezuelan Andes.
Marcano, V; Morales Méndez, A; Rodriguez-Alcocer, V, 1999
)
1.39
"Usnic acid has been incorporated for years in cosmetics, perfumery, and traditional medicines."( Usnic acid and its derivatives for pharmaceutical use: a patent review (2000-2017).
Luzina, OA; Salakhutdinov, NF, 2018
)
2.64
"(+)-Usnic acid (UA) has been known to be a strong uncoupler, and mitochondrial and endoplasmic reticulum (ER)-related stresses are suggested to be involved in the mechanism of hepatotoxicity. "( (+)-Usnic acid-induced myocardial toxicity in rats.
Imaoka, M; Jindo, T; Kiyosawa, N; Niino, N; Sayama, A; Yokouchi, Y, 2015
)
1.53
"Usnic acid has been shown to exhibit antiviral, antiprotozoal, antiproliferative, anti-inflammatory, and analgesic activity."( Ultrastructural analysis of Leishmania infantum chagasi promastigotes forms treated in vitro with usnic acid.
Alves, LC; da Luz, JS; da Silva, LL; da Silva, NH; de Medeiros, PL; de Oliveira, EB; dos Santos, FA; Martins, MC; Silva, EC, 2015
)
1.36
"Usnic acid (UA) has been associated with chronic diseases through its antioxidant action. "( An in vitro study on the antioxidant capacity of usnic acid on human erythrocytes and molecular models of its membrane.
Astudillo, C; Gallardo, MJ; Jemiola-Rzeminska, M; Staforelli, JP; Strzalka, K; Suwalsky, M; Villena, F, 2015
)
2.11
"Usnic acid has been progressively reported in the literature as one of the most important lichen metabolites characterized by a rich diversity of applications such as antifungal, antimicrobial, antiprotozoal and antiviral agent. "( Bactericidal Activity of Usnic Acid-Loaded Electrospun Fibers.
Araújo, ES; da Costa, MM; da Silva, NH; de Oliveira, HP; Pereira, EC, 2016
)
2.18
"(+)-Usnic acid has a remarkable effect on T. "( [In vitro effect of (+)-usnic acid on Toxoplasma gondii tachyzoites].
Cheng, YB; Gu, N; Li, C; Li, XQ; Si, KW; Wei, LL; Yuan, YK, 2008
)
1.21
"Usnic acid has a strong and dose-dependent activity against H."( In vitro anti-Helicobacter pylori activity of usnic acid.
Aktepe, OC; Altindis, M; Asik, G; Cetinkaya, Z; Ciftci, IH; Kiyildi, N; Ozdemir, M; Safak, B, 2009
)
1.33
"Usnic acid has been an ingredient of dietary supplements that cause liver failure."( Fulminant liver failure due to usnic acid for weight loss.
Busuttil, RW; Durazo, FA; Farmer, DG; Ghobrial, M; Goldstein, RL; Gordon, S; Han, SH; Kawano, M; Lassman, C; Lee, NP; Saab, S; Saggi, B; Yersiz, H, 2004
)
1.33
"Usnic acid has several interesting biological properties."( Antimitotic effects of usnic acid on different biological systems.
Alesiani, O; Campanella, L; Cardarelli, M; De Cicco Nardone, F; Ercole, P; Rossiello, F; Serino, G, 1997
)
1.33
"Usnic acid has a reported antibiotic activity and the lichen is utilized for medicinal purposes by Andean farmers."( Occurrence of usnic acid in Usnea laevis Nylander (lichenized ascomycetes) from the Venezuelan Andes.
Marcano, V; Morales Méndez, A; Rodriguez-Alcocer, V, 1999
)
1.39

Actions

ExcerptReferenceRelevance
"(+)-Usnic acid tended to increase the percentage of early apoptotic cells and LC3 protein, autophagy marker."( (+)-Usnic acid modulates the Nrf2-ARE pathway in FaDu hypopharyngeal carcinoma cells.
Baer-Dubowska, W; Kleszcz, R; Krajka-Kuźniak, V; Paluszczak, J, 2021
)
1.66

Treatment

Usnic acid treatment was associated with early inhibition and uncoupling of the electron transport chain in mitochondria of cultured hepatocytes.

ExcerptReferenceRelevance
"Usnic acid (10-25 μM) treatment to these cells caused a significant increase in mitochondrial membrane depolarization and apoptotic cells."( Usnic acid induces apoptosis in human gastric cancer cells through ROS generation and DNA damage and causes up-regulation of DNA-PKcs and γ-H2A.X phosphorylation.
Kumar, K; Mishra, JPN; Singh, RP, 2020
)
2.72
"Usnic acid treatment was associated with early inhibition and uncoupling of the electron transport chain in mitochondria of cultured hepatocytes."( Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress.
Han, D; Kaplowitz, N; Matsumaru, K; Rettori, D, 2004
)
2.49

Toxicity

The median toxic dose (ED(50) of (+)-usnic acid in domestic sheep was estimated to be between 485 and 647 mg/kg/day for 7 days.

ExcerptReferenceRelevance
" The median toxic dose (ED(50)) of (+)-usnic acid in domestic sheep was estimated to be between 485 and 647 mg/kg/day for 7 days."( Toxicity of the lichen secondary metabolite (+)-usnic acid in domestic sheep.
Dailey, RN; Ingram, JT; Montgomery, DL; Raisbeck, MF; Siemion, R; Vasquez, M, 2008
)
0.87
"The mice with acute poisoning of (+)-usnic acid at different doses by oral administration were observed for toxic manifestations, and the LD(50) was determined."( [Oral acute toxicity of (+)-usnic acid in mice and its cytotoxicity in rat cardiac fibroblasts].
Cheng, YB; Gu, N; Li, C; Li, XQ; Shi, L; Si, KW; Wei, LL; Yuan, YK, 2009
)
0.92
" These data demonstrate that UA is bio-transformed to less toxic metabolites in rat primary hepatocytes, probably mainly by CYP1A and 3A, but not 2B/2C."( Inhibition of cytochrome P450s enhances (+)-usnic acid cytotoxicity in primary cultured rat hepatocytes.
Greenhaw, J; Salminen, WF; Shi, Q, 2014
)
0.66
" Mitochondrial imbalance with complex stresses may be involved in the toxic mechanism."( (+)-Usnic acid-induced myocardial toxicity in rats.
Imaoka, M; Jindo, T; Kiyosawa, N; Niino, N; Sayama, A; Yokouchi, Y, 2015
)
0.98
" In conclusion, amino acid limitation was suggested as the pivotal toxic trigger of UA-induced cardiotoxicity."( Comprehensive Evaluation of (+)-Usnic Acid-induced Cardiotoxicity in Rats by Sequential Cross-omics Analysis.
Imaoka, M; Kai, K; Kiyosawa, N; Niino, N; Yokouchi, Y, 2017
)
0.74

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma usnic acid levels following intravenous administration showed a triexponential elimination with a mean +/- SD terminal half-life of 10."( Pharmacokinetics of D(+)-usnic acid in rabbits after intravenous and oral administration.
Krishna, DR; Venkataramana, D,
)
0.87
" The pharmacokinetic parameters obtained from a three-compartment body model and a noncompartment body model gave close values."( Pharmacokinetics of d(+)-usnic acid in rabbits after intravenous administration.
Krishna, DR; Venkataramana, D,
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"The in vitro antimicrobial activities of usnic acid were evaluated in combination with five therapeutically available antibiotics, using checkerboard microdilution assay against methicillin-resistant clinical isolates strains of Staphylococcus aureus."( In vitro interaction of usnic acid in combination with antimicrobial agents against methicillin-resistant Staphylococcus aureus clinical isolates determined by FICI and ΔE model methods.
Amicosante, G; Bellio, P; Brisdelli, F; Celenza, G; Garbarino, JA; Nicoletti, M; Perilli, M; Piovano, M; Segatore, B; Setacci, D, 2012
)
0.95
" The Tdp1 inhibitor OL7-43 was used in combination with olaparib to increase the antitumor effect of the latter."( [Effect of Usnic Acid-Derived Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Used as Monotherapy or in Combination with Olaparib on Transplanted Tumors In Vivo].
Chepanova, AA; Dyrkheeva, NS; Filimonov, AS; Ilina, ES; Kornienko, TE; Lavrik, OI; Luzina, OA; Nikolin, VP; Popova, NA; Salakhutdinov, NF; Zakharenko, AL; Zakharova, OD,
)
0.52

Bioavailability

ExcerptReferenceRelevance
" Mean absolute bioavailability of usnic acid following oral administration was 77."( Pharmacokinetics of D(+)-usnic acid in rabbits after intravenous and oral administration.
Krishna, DR; Venkataramana, D,
)
0.71
"The wet-milling technique was suitable for the preparation of UA nanocrystal suspension, and a new nanosystem of UA with higher solid content and higher bioavailability was achieved."( Preparation and evaluation of wet-milled usnic acid nanocrystal suspension for better bioaffinity.
Du, X; Qu, C; Tu, P; Zhang, L; Zhang, X; Zhao, Y; Zheng, J, 2018
)
0.75
" The main idea to be addressed in the future should include the synthesis of UA derivatives because these might possess increased bioactivity, bioavailability and decreased toxicity."( Usnic acid and its derivatives for pharmaceutical use: a patent review (2000-2017).
Luzina, OA; Salakhutdinov, NF, 2018
)
1.92
" Additionally, an overview of the main strategies adopted so far to reduce drug toxicity and increase bioavailability is given in the perspective of a safe use of UA in the clinical management of infected wounds."( Usnic Acid: Potential Role in Management of Wound Infections.
Donelli, G; Francolini, I; Piozzi, A, 2019
)
1.96
" KU showed increased bioavailability compared with UA in the tumor, liver, and plasma of a CT26 syngeneic mouse tumor xenograft model after oral administration, as determined by LC-MS/MS analysis."( Potassium usnate, a water-soluble usnic acid salt, shows enhanced bioavailability and inhibits invasion and metastasis in colorectal cancer.
Bae, WK; Choi, YJ; Chung, IJ; Gamage, C; Ha, HH; Hur, JS; Kim, H; Kim, KK; Kim, SK; Lee, JH; Lee, JY; Lee, KH; Paik, MJ; Park, MS; Park, SY; Taş, İ; Yang, Y; Yu, YH; Zhou, R, 2018
)
0.76
" Adhesive polymeric films were designed to improve UA use by enhancing its bioavailability in the wounded tissues."( Bioadhesive polymeric films based on usnic acid for burn wound treatment: Antibacterial and cytotoxicity studies.
Calarco, P; Ceccarini, MR; Conte, C; Pagano, C; Perioli, L; Primavilla, S; Ricci, M; Scuota, S, 2019
)
0.79
" Nevertheless, chemical instability and low solubility of OXY in aqueous solutions reduce its bioavailability and hinder it from exerting neuroprotective activities."( Alkoxy glycerol enhanced activity of Oxyresveratrol in Alzheimer's disease by rescuing Tau protein.
Elumalai, P; Lakshmi, S; Sivan, S; Varija Raghu, S, 2021
)
0.62
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" To test the hypothesis that usnic acid is the proximate cause of death in animals poisoned by lichen, domestic sheep were dosed PO with (+)-usnic acid."( Toxicity of the lichen secondary metabolite (+)-usnic acid in domestic sheep.
Dailey, RN; Ingram, JT; Montgomery, DL; Raisbeck, MF; Siemion, R; Vasquez, M, 2008
)
0.89
" In liver sections of 200 and 240 mg/kg dosage groups, widespread hydropic degeneration of hepatocytes was observed."( A metabonomic characterization of (+)-usnic acid-induced liver injury by gas chromatography-mass spectrometry-based metabolic profiling of the plasma and liver in rat.
Fan, X; Jin, T; Lu, X; Tian, Y; Xiao, S; Zhao, Q, 2011
)
0.64
" The UA-Lipo may be used as a dosage form to improve the antimycobacterial activity of RIF, a first-line drug for the treatment of infections caused by Mtb."( Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates.
Cavalcanti, IM; Ferraz-Carvalho, RS; Linhares, LA; Lira-Nogueira, MC; Montenegro, LM; Pereira, MA; Santos-Magalhães, NS, 2016
)
0.72
" For two of the derivatives, BT37 and BT122, we observed a consistent dose-response relationship between concentration in the blood meal and oocyst intensity in the midgut."( A Malaria Transmission-Blocking (+)-Usnic Acid Derivative Prevents Plasmodium Zygote-to-Ookinete Maturation in the Mosquito Midgut.
Delves, M; Dinglasan, RR; King, JG; Mathias, DK; Pastrana-Mena, R; Rajaram, K; Trucchi, B; Verotta, L; Yee, R, 2016
)
0.71
" In rats, oral absorption of nanocrystal UA were superior to the ordinary groups, with the 348% of the maximum concentration and 181% of the AUC after the same dosage administration."( Preparation and evaluation of wet-milled usnic acid nanocrystal suspension for better bioaffinity.
Du, X; Qu, C; Tu, P; Zhang, L; Zhang, X; Zhao, Y; Zheng, J, 2018
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
lichen metaboliteAny metabolite that is produced during a metabolite reaction in lichens (composite organisms consisting of a fungus and a photosynthetic partner co-existing in a symbiotic relationship).
acaricideA substance used to destroy pests of the subclass Acari (mites and ticks).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
benzofurans
dibenzofuransAny organic heterotricyclic compound based on a dibenzofuran skeleton and its substituted derivatives thereof.
methyl ketoneA ketone of formula RC(=O)CH3 (R =/= H).
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.79430.003245.467312,589.2998AID2517
Chain A, Breast cancer type 1 susceptibility proteinHomo sapiens (human)Potency31.62281.258920.440939.8107AID875
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
DNA polymerase kappa isoform 1Homo sapiens (human)Potency39.81070.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.15850.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency7.07950.177814.390939.8107AID2147
EWS/FLI fusion proteinHomo sapiens (human)Potency0.00420.001310.157742.8575AID1259253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID1539071Cell cycle arrest in human HeLa cells assessed as accumulation of cells at S phase at 8.7 uM after 24 hrs by propidium iodide staining based flow cytometric analysis
AID1539058Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
AID1539068Induction of cell cycle arrest in human MCF7 cells assessed as accumulation of cells at S phase at 8.7 uM after 24 hrs by Propidium iodide staining based flow cytometric analysis (Rvb = 23.75 +/- 1.87%)
AID1539069Induction of cell cycle arrest in human MCF7 cells assessed as accumulation of cells at G2/M phase at 2.9 uM after 24 hrs by Propidium iodide staining based flow cytometric analysis (Rvb = 27 +/- 2.97%)
AID1539056Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
AID1539066Induction of cell cycle arrest in human MCF7 cells assessed as accumulation of cells at G0/G1 phase at 8.7 uM after 24 hrs by Propidium iodide staining based flow cytometric analysis (Rvb = 47.8 +/- 0.42%)
AID1539054Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
AID1539061Cytotoxicity against human HDFa cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID1539065Induction of cell cycle arrest in human MCF7 cells assessed as accumulation of cells at G0/G1 phase at 2.9 uM after 24 hrs by Propidium iodide staining based flow cytometric analysis (Rvb = 47.8 +/- 0.42%)
AID1539059Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID1539055Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID1539072Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G2/M phase at 8.7 uM after 24 hrs by propidium iodide staining based flow cytometric analysis
AID1539060Cytotoxicity against human HDFa cells assessed as reduction in cell viability after 24 hrs by MTT assay
AID1539057Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID1539070Induction of cell cycle arrest in human MCF7 cells assessed as accumulation of cells at G2/M phase at 8.7 uM after 24 hrs by Propidium iodide staining based flow cytometric analysis (Rvb = 27 +/- 2.97%)
AID1539067Induction of cell cycle arrest in human MCF7 cells assessed as accumulation of cells at S phase at 2.9 uM after 24 hrs by Propidium iodide staining based flow cytometric analysis (Rvb = 23.75 +/- 1.87%)
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1412919Antibacterial activity against Staphylococcus aureus ATCC 6538 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412929Bactericidal activity against Bacillus cereus clinical isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412943Fungicidal activity against Trichoderma viride IAM 5061 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412944Fungicidal activity against Aspergillus niger by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412932Bactericidal activity against Escherichia coli ATCC 35210 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412927Bactericidal activity against Staphylococcus aureus ATCC 6538 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412939Antifungal activity against Trichoderma viride IAM 5061 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412947Fungicidal activity against Aspergillus fumigatus ATCC 1022 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412925Antibacterial activity against drug-resistant Escherichia coli by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412940Antifungal activity against Penicillium funiculosum ATCC 36839 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412942Fungicidal activity against Penicillium funiculosum ATCC 36839 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412926Antibacterial activity against Enterobacter cloacae clinical isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412928Bactericidal activity against methicillin-resistant Staphylococcus aureus by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412945Fungicidal activity against Aspergillus ochraceus by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1866439Antiproliferative activity against human MCF7 cells2022Journal of natural products, 03-25, Volume: 85, Issue:3
Discovery of Anticancer Agents of Diverse Natural Origin.
AID1412931Bactericidal activity against drug-resistant Pseudomonas aeruginosa PAO1 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412948Antifungal activity against Penicillium verrucosum var. cyclopium food isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412935Antifungal activity against Aspergillus fumigatus ATCC 1022 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412921Antibacterial activity against Bacillus cereus clinical isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412937Antifungal activity against Aspergillus ochraceus by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412933Bactericidal activity against drug-resistant Escherichia coli by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1866440Antiproliferative activity against human A2780 cells2022Journal of natural products, 03-25, Volume: 85, Issue:3
Discovery of Anticancer Agents of Diverse Natural Origin.
AID1546638Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as reduction in microbial growth after 7 days by alamar blue assay2020Journal of natural products, 01-24, Volume: 83, Issue:1
Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.
AID1412922Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412920Antibacterial activity against methicillin-resistant Staphylococcus aureus by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412934Bactericidal activity against Enterobacter cloacae clinical isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412930Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1311351Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Click-based synthesis and antitubercular evaluation of dibenzofuran tethered thiazolyl-1,2,3-triazolyl acetamides.
AID1412924Antibacterial activity against Escherichia coli ATCC 35210 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412938Antifungal activity against Aspergillus niger by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412946Fungicidal activity against Aspergillus versicolor ATCC 11730 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412949Fungicidal activity against Penicillium ochrochloron ATCC 9112 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412950Fungicidal activity against Penicillium verrucosum var. cyclopium food isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412936Antifungal activity against Aspergillus versicolor ATCC 11730 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412941Antifungal activity against Penicillium ochrochloron ATCC 9112 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412923Antibacterial activity against drug-resistant Pseudomonas aeruginosa PAO1 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1391358Antimycobacterial activity against Mycobacterium tuberculosis2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Dibenzofuran, dibenzothiophene and N-methyl carbazole tethered 2-aminothiazoles and their cinnamamides as potent inhibitors of Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (387)

TimeframeStudies, This Drug (%)All Drugs %
pre-199046 (11.89)18.7374
1990's14 (3.62)18.2507
2000's69 (17.83)29.6817
2010's176 (45.48)24.3611
2020's82 (21.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.77 (24.57)
Research Supply Index6.01 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index72.19 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (46.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.25%)5.53%
Trials0 (0.00%)5.53%
Reviews19 (4.69%)6.00%
Reviews0 (0.00%)6.00%
Case Studies10 (2.47%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other375 (92.59%)84.16%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]